Sun Pharmaceutical Industries (SUNPHARMA) investor relations material

Business overview and global presence

• Operates in over 100 countries with a diversified portfolio including innovative medicines, branded generics, generics, and APIs.

• Largest pharma company in India and 13th largest in US generics market.

• 40 manufacturing facilities across six continents, many approved by global regulators.

• Over 43,000 employees worldwide.

• Expanding presence in ex-US developed markets and emerging markets.

Revenue composition and growth

• FY25 sales reached Rs 520 Bn, with India formulations at 33%, US at 31%, Emerging Markets at 18%, ROW at 14%, and API & Others at 4%.

• Sales CAGR of 19% from FY10 to FY25; EBITDA CAGR of 18%.

• Innovative Medicines contributed 20% of FY25 sales, up from 7.3% in FY18.

• US and India are the largest revenue contributors.

Profitability and financial performance

• FY25 gross margin at 79.3%, EBITDA margin at 29%, and adjusted net profit margin at 22.8%.

• ROCE at 20.5% and ROE at 17.4% for FY25.

• Market capitalization of US $45 Bn as of Feb 2026.

• Net cash from operating activities at Rs 121.4 Bn in FY25.

• Maintains best-in-class profitability among Indian pharma peers.